Applied DNA Launches Mpox Clade I and Clade II Testing Service
STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for both mpox Clade I and Clade II. The launch of the expanded mpox testing service comes after ADCL's interaction with relevant regulatory bodies, including the New York State Department of Health (NYSDOH) and the U.S. Food and Drug Administration (FDA).
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Ginkgo Bioworks hopes to revolutionize many industries with bioengineered products. Its business, however, remains deeply unprofitable.
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
- Pilot Project To Demonstrate Effectiveness of CertainT® for Cotton Textile Traceability - STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the receipt of a subcontract award from LRQA following a competitive tender for a pilot isotopic testing program. Under the terms of the subcontract, Applied DNA, together with its traceability partner, Isotech (a Stratum Reservoir company), will employ CertainT® to conduct isotopic testing and analysis to support cotton traceability in Pakistan.
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue.
This 1 AI Stock Could Revolutionize Biotech and Pharma
Ginkgo Bioworks seeks to create a high-throughput biopharma services platform. So far, that platform isn't profitable, but it can still generate a lot of scientific data.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
From Promise to Peril: The Downfall of Ginkgo Bioworks
“Our revenue has grown substantially, and we are proud of the progress we've made in establishing strategic partnerships. The robust pipeline of projects we have in place positions us well for continued financial success.
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
Ginkgo Bioworks is still not anywhere close to being operationally profitable. Management isn't planning on it becoming profitable anytime soon.
Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
Applied DNA Sciences, Inc. APDN stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro.
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
-Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II- STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of Health (NYSDOH) in support of an expansion of the permitted use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include both mpox clade I and clade II. The Company's validation studies concluded that the Assay's primers and probe have 100% homology to mpox clade I and clade Ib, the latter of which was the subject of the World Health Organization's (WHO) recently declared public health emergency of international concern.
Ginkgo Bioworks: Here Comes The Test
Ginkgo Bioworks has struggled with missed revenue targets, leading to a significant decline in share value. The recent Q2 report showed a 30% decrease in total revenues, with cost structure still a major issue for the company. Balance sheet weakening as cash reserves decrease, putting pressure on working capital and financial flexibility.
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its intention to seek an expansion of the approved intended use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include the detection of mpox Clade I that is the subject of the World Health Organization's (WHO) 14 August 2024 declaration of a public health emergency of international concern (PHEIC). The Company's internally generated data show that the Assay can detect the genetic sequence of mpox Clade I and is now undertaking validation studies to enable the filing of necessary documentation with the New York State Department of Health (NYSDOH).
